Phase 2 Study Of Alprazolam

Brief description of study

The purpose of this research is to test whether a single-use, hand-held, drug-device combination product called STAP-001 is effective, safe and easy to use in a clinical setting. STAP-001 provides quick delivery of the study drug (alprazolam) to all parts of the body by having subjects breathe in an aerosol form of alprazolam. Alprazolam is approved for the management of anxiety disorder, or the short-term relief of symptoms of anxiety, and for the treatment of panic disorder. Alprazolam is in a class of approved drugs called benzodiazepines that are used for emergency treatment of seizures. However, alprazolam is not yet approved for the treatment of seizures. In this study the device and the use of an aerosol form of alprazolam are experimental, and their use to treat acute seizures has not been approved by the U.S. Food and Drug Administration.


Clinical Study Identifier: s17-01387
ClinicalTrials.gov Identifier: NCT03478982
Principal Investigator: Blanca Vazquez
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.